Evidence map›Paper›PMID 40274278›Full record

ArticleBMJ open diabetes research & care2025

GLP-1 RA and dual GIP/GLP-1 RA treatment in MODY: a descriptive case series.

Alina Z Mehdi, Lily Deng, Colby L Chase, Maria Cristina Foss-Freitas, Brigid Gregg, Rochelle N Naylor, Elif A Oral, William H Herman, Mansa Krishnamurthy, David T Broome

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open diabetes research & care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Pooled it
  2. Article
  3. Article
  4. Diabetes mellitusFrontiers in endocrinology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alina Z MehdiDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Lily DengDivision of Endocrinology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Colby L ChaseDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Maria Cristina Foss-FreitasDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Brigid GreggDepartment of Pediatrics, Division of Pediatric Endocrinology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Rochelle N NaylorDepartment of Pediatrics and Medicine, Section of Endocrinology, Diabetes and Metabolism, The University of Chicago, Chicago, Illinois, USA.
Elif A OralDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID http://orcid.org/0000-0002-9171-1144
William H HermanDivision of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID http://orcid.org/0000-0002-0502-674X
Mansa KrishnamurthyEndocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.ORCID http://orcid.org/0000-0001-8178-0886
David T BroomeDepartment of Metabolism, Endocrinology and Diabetes (MEND), University of Michigan Michigan Medicine, Ann Arbor, Michigan, USA broomeda@med.umich.edu.ORCID http://orcid.org/0000-0002-4964-7716

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
NIDDK NIH HHS P30 DK020572
6 · The paper itself

Abstract

introductionGlucagon-like peptide-1 receptor agonists (GLP-1 RA) and dual glucose insulinotropic polypeptide (GIP)/GLP-1 RA are widely prescribed, but their effectiveness in different subtypes of maturity-onset diabetes of the young (MODY) is unknown. RESEARCH DESIGN AND

methodsWe present a descriptive case series of individuals from two MODY cohorts who used GLP-1 RA or dual GIP/GLP-1 RA. Paired

results10 individuals (4 hepatocyte nuclear factor-1α (HNF1A)-MODY, 4 hepatocyte nuclear factor-4α (HNF4A)-MODY, 1 ATP-binding cassette transporter subfamily C member 8 (ABCC8)-MODY, 1 hepatocyte nuclear factor-1β (HNF1B)-MODY) were identified who used GLP-1 RA or dual GIP/GLP-1 RA. In patients with HNF1A-MODY and HNF4A-MODY, GLP-1 RA reduced HbA1c by 1.3% (p=0.010), BMI by 2.90 kg/m

conclusionsGLP-1 RA and dual GIP/GLP-1 RA lowered HbA1c, BMI, and SU dose in patients with MODY.

Indexed as

Diabetes Mellitus, Type 2Gastric Inhibitory PolypeptideGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsAdultBiomarkersBlood GlucoseBody Mass IndexDrug Therapy, CombinationFemaleFollow-Up StudiesGlucagon-Like Peptide 1Glycated HemoglobinHumansMaleMiddle AgedBiomarkersBlood GlucoseGastric Inhibitory PolypeptideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsSulfonylurea CompoundsDiabetes Mellitus, ExperimentalGeneticsGlucagon-Like Peptide 1Glycated Hemoglobin A

Identifiers

PMID40274278
PMCPMC12020758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.